As more men become aware of the bad news regarding the side effects of testosterone products, the sale of testosterone prescriptions has been falling significantly. The most dramatic decline took place between 2013 and 2016 in the wake of public warnings from the FDA that such products increase the risk of heart attack, stroke, and prostate cancer.
The second bellwether trial involving the testosterone-boosting product Androgel ended Thursday in a verdict for the plaintiff. The jury found that the manufacturer, AbbVie, had failed to properly test the product in order to determine whether it posed a danger of heart attack, and deliberately engaged in false advertising, marketing the product to men whose low testosterone levels were due to natural causes associated with the aging process.
An Illinois federal jury has ruled that the pharmaceutical company AbbVie, Inc., must pay $150,000,000 in punitive damages to a former user of AndroGel, a testosterone replacement medication. The case was heard in federal court in Chicago, Illinois. Jurors deliberated nearly five hours, over the course of two days, before finding that AbbVie falsely marketed the drug and was liable for fraud.
FDA Warns Testosterone Not Approved for Low Testosterone Due to Aging and May Cause Heart Attack and Stroke; Requires Label Change
The U.S. Food and Drug Administration (FDA) issued a Safety Announcement on March 3 warning the public that testosterone products are not approved for use in treating low testosterone as a result of aging.
In November of 2013, a research study, carried out at a Veteran's Administration facility, appeared in the Journal of the American Medical Association. The conclusion:
“Among a cohort of men in the VA health care system who underwent coronary angiography and had a low serum testosterone level, the use of testosterone therapy was associated with increased risk of adverse outcomes” (Vigen, et. al.)
In other words, the use of supplemental testosterone appeared to be connected with heart attacks among the research subjects.
“T-pushers” continue to hype their products to normal, healthy men who are encouraged to “T it up,” despite continuing news about the potential adverse consequences to a user’s health. These include increased risk of heart attack, stroke and even developing prostate cancer. It's still a big seller, however, even while the number of lawsuits against these manufacturers continues to grow.
A recent Swiss study now strongly suggests that the overuse of testosterone could have consequences for society as a whole.
It's no secret that Americans – held captive by a corporate, for-profit health care “system” (the ACA notwithstanding) – are the most over-medicated people on the planet. In its insatiable quest to maximize profits at any cost, Big Pharma will “identify” or even create so-called “conditions” and “health problems,” then use fear to sell patients their solutions – which, more often than not, cause side effects ranging from mildly irritating to deadly.
With the September 17th recommendations from a panel of Food and Drug Administration advisors that the agency impose strict new limitations on the multi-billion dollar testosterone drug industry, the secret behind the marketing of these products, like AndroGel®, has been revealed. The smoke and mirrors pitch that these drugs will help the average male feel more alive, more energetic, and more youthful has been sufficiently debunked.